Evidence map›Paper›PMID 32587098›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2020

Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice.

Robert S Jones, Donna Ruszaj, Mark D Parker, Marilyn E Morris

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Robert S JonesDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences (R.S.J., D.R., M.E.M.) and Department of Physiology and Biophysics, Jacobs School of Medicine and Biomedical Sciences (M.D.P.), University at Buffalo, State University of New York, Buffalo, New York.ORCID 0000-0002-5283-8070
Donna RuszajDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences (R.S.J., D.R., M.E.M.) and Department of Physiology and Biophysics, Jacobs School of Medicine and Biomedical Sciences (M.D.P.), University at Buffalo, State University of New York, Buffalo, New York.
Mark D ParkerDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences (R.S.J., D.R., M.E.M.) and Department of Physiology and Biophysics, Jacobs School of Medicine and Biomedical Sciences (M.D.P.), University at Buffalo, State University of New York, Buffalo, New York.
Marilyn E MorrisDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences (R.S.J., D.R., M.E.M.) and Department of Physiology and Biophysics, Jacobs School of Medicine and Biomedical Sciences (M.D.P.), University at Buffalo, State University of New York, Buffalo, New York memorris@buffalo.edu.ORCID 0000-0003-1127-7964
University at Buffalo, State University of New York · US

Funding

Gamma-Hydroxybutyrate: Toxicokinetics, Toxicodynamics and Treatment StrategiesR01DA023223 · NIDA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MORRIS, MARILYN E · 2008 to 2016
$3.0M
NIDA NIH HHS R01 DA023223
6 · The paper itself

Abstract

Bumetanide, a sulfamyl loop diuretic, is used for the treatment of edema in association with congestive heart failure. Being a polar, anionic compound at physiologic pH, bumetanide uptake and efflux into different tissues is largely transporter-mediated. Of note, organic anion transporters (SLC22A) have been extensively studied in terms of their importance in transporting bumetanide to its primary site of action in the kidney. The contribution of one of the less-studied bumetanide transporters, monocarboxylate transporter 6 (MCT6; SLC16A5), to bumetanide pharmacokinetics (PK) and pharmacodynamics (PD) has yet to be characterized. The affinity of bumetanide for murine Mct6 was evaluated using Mct6-transfected

Indexed as

Administration, IntravenousAdministration, OralAnimalsBumetanideDiuresisDrug Evaluation, PreclinicalKidney CortexMaleMiceMice, KnockoutMonocarboxylic Acid TransportersOocytesRecombinant ProteinsSodium Potassium Chloride Symporter InhibitorsXenopus laevisBumetanideMonocarboxylic Acid TransportersRecombinant ProteinsSlc16a5 protein, mouseSodium Potassium Chloride Symporter Inhibitors

Identifiers

PMID32587098
PMCPMC7469248
OpenAlexW3037739145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.